Introduction {#s0005}
============

Epithelial ovarian cancer (EOC) causes more deaths than any other malignancy affecting the female reproductive system. In up to 75% of the patients, the disease is diagnosed at an advanced stage, with peritoneal involvement or distant metastasis \[International Federation of Gynecology and Obstetrics (FIGO) stage III to IV\], and for such patients. the overall 5-year survival rate is less than 20% [@bb0005].

The standard treatment of advanced EOC is based on optimal cytoreductive surgery (CRS) to remove all the visible tumors if possible, followed commonly by intravenous platinum/taxane-based chemotherapy [@bb0010], [@bb0015]. However, even after the best standard treatment, optimal CRS and platinum/taxane-based chemotherapy, 60% to 70% of advanced EOC patients experience a relapse, mostly in the form of peritoneal carcinomatosis (PC) [@bb0020]. There has been no curative treatment for EOC PC. Repeated conventional chemotherapy alone or in combination with molecular targeting agents could improve survival and quality of life at the cost of considerable treatment-related adverse events [@bb0025], [@bb0030].

Over the past three decades, aggressive CRS plus hyperthermic intraperitoneal chemotherapy (HIPEC) has been developed as a comprehensive treatment package integrating multivisceral resections to remove the macroscopic tumor and HIPEC to eradicate the microscopic residual disease. In China, we have conducted a series of preclinical and clinical studies on the feasibility, efficacy, and safety of this multidisciplinary treatment approach in animal models [@bb0035] and in clinical setting [@bb0040], [@bb0045]. The benefits of this treatment package have been demonstrated in PC patients from gastric cancer [@bb0045], [@bb0050], colorectal cancer [@bb0055], pseudomyxoma peritonei, and peritoneal mesothelioma. As a result, a regional PC center has been set up, and a prospective database has been established. In this report, we summarized our experience in 50 CRS+HIPEC procedures for the treatment of 46 EOC patients.

Patients and Methods {#s0010}
====================

Patient Selection {#s0015}
-----------------

This is a retrospective cohort study on prospectively established database covering 46 consecutive Chinese patients with advanced EOC (FIGO stage IIIc/IV, *n* = 16, group A) or recurrent EOC with PC (*n* = 30, group B), aged from 22 to 75 years old (median 57.5 years), treated by 50 CRS+HIPEC procedures from March 2005 to September 2014. Among the 30 patients in the recurrent group were 25 patients at the first recurrence, 3 patients at the second recurrence, and 2 patients at the third recurrence. The inclusion criteria were 1) age 20 to 75 years; 2) Karnofsky performance status \> 50; 3) peripheral blood white blood cells count ≥ 3500/mm^3^ and platelet count ≥ 80,000/mm^3^; 4) acceptable liver function, with bilirubin ≤ 2 × the upper limit of normal (ULN) and aspartic aminotransferase and alanine aminotransferase ≤ 2 × ULN; 5) acceptable renal function, with serum creatinine ≤ 1.5 mg/dl; and 6) cardiovascular pulmonary and other major organ functions could stand major operation. Major exclusion criteria were 1) age \< 20 years or \> 75 years; 2) any lung metastasis, liver metastasis, or prominent retroperitoneal lymph node metastasis during preoperative assessment; 3) serum bilirubin level \> 3 × ULN; 4) liver enzymes \> 3 × ULN; and 5) serum creatinine level \> 1.5 mg/dl. Informed consent was obtained from all patients, and the study was approved by the institutional review board and the ethics committee.

CRS plus HIPEC Procedure {#s0020}
------------------------

All CRS+HIPEC procedures were conducted by a designated team focusing on PC treatment. In brief, the abdominal exploration was performed through a midline xiphoid-pubic incision after general anesthesia, and peritoneal cancer index (PCI) was evaluated and recorded according to Sugarbaker\'s criteria [@bb0060]. Then maximal CRS was performed. The extent of CRS was determined by Sugarbaker\'s criteria [@bb0065] on the completeness of cytoreduction (CC). A score of CC 0 indicates no residual peritoneal disease after CRS; CC 1, less than 2.5 mm of residual disease; CC 2, residual tumor between 2.5 mm and 2.5 cm; and CC 3, more than 2.5 cm of residual tumor or the presence of a sheet of unresectable tumor nodules.

After CRS, open HIPEC was implemented with cisplatin 100 mg/m^2^ and mitomycin C (MMC) 20 mg/m^2^ in 35 cases, and paclitaxel 100 mg/m^2^ and lobaplatin 50 mg/m^2^ in 15 cases with increased risk of renal dysfunctions, each dissolved in 6 l of heated saline at temperature of 43.0 ± 0.5°C. The total HIPEC time was 60 minutes, after which gastrointestinal anastomoses or stomata were made. After operation, the patient was delivered to the intensive care unit for recovery. When the condition stabilized, the patients were transferred to the surgical oncology ward.

Postoperative Chemotherapy {#s0025}
--------------------------

Postoperative adjuvant chemotherapy was delivered within 2 to 3 weeks after CRS+HIPEC, including platinum/taxane-based systemic chemotherapy (SC) and perioperative intraperitoneal chemotherapy (PIC) through the intraperitoneal chemotherapy port once every 3 to 4 weeks mainly using cisplatin 100 mg/m^2^ and paclitaxel 100 mg/m^2^. For platinum-resistant disease, paclitaxel 100 mg/m^2^ and doxorubicin 35 mg/m^2^ were used. The median cycles of postoperative adjuvant chemotherapy (SC and/or PIC) were 6 (range, 0-26), and the median cycles of postoperative PIC were 3 (range, 0-9).

Study Endpoints and Definition {#s0030}
------------------------------

The primary endpoints of this study were progression-free survival (PFS) calculated from the date of CRS+HIPEC to the date of disease progression and the overall survival (OS) defined as the time interval from the first treatment to death due to the disease. Patients with recurrent EOC were further divided into platinum-sensitive or -resistant subgroups according to the established criteria [@bb0070]. The secondary endpoints were the perioperative serious adverse events (SAEs), defined as complications directly attributable to the treatment within 30 days of CRS+HIPEC, based on the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 [@bb0075].

Follow-Up {#s0035}
---------

All patients were regularly followed up once every 3 months for the first 2 years and every 6 months thereafter for detailed information on disease status. Patients alive at the time of analysis were censored at the last follow-up. The follow-up package included physical examination, serum tumor markers (CA125, CEA, and CA19-9), and imaging examination, with the most recent follow-up on February 28, 2015. No patient was lost to follow-up.

Statistical Analysis {#s0040}
--------------------

The patient information was systematically integrated into a prospectively established database. Data analysis was conducted using the Statistical Package for Social Sciences version 17.0 (SPSS, Inc., Chicago, IL). The numerical data were directly recorded, and the category data were recorded into different categories. The Kaplan-Meier method was used to compare the survival with log-rank test, and multivariate Cox regression analysis was performed to delineate the independent predictors. Subgroup OS comparisons were performed by HIPEC timing (primary versus recurrent), PCI \[low PCI (LPCI) versus high PCI (HPCI)\] (PCI ≤ 20 defined as LPCI, and PCI \> 20 defined as HPCI), and CC score (CC 0-1 vs CC 2-3). A two-sided *P* \< .05 was considered as statistically significant.

Results {#s0045}
=======

Major Clinical and Pathological Characteristics of the Patients {#s0050}
---------------------------------------------------------------

A total of 46 patients with stage IIIc/IV EOC (*n* = 16) and recurrent EOC (*n* = 30) were treated with 50 CRS+HIPEC procedures, including 4 patients each receiving 2 CRS+HIPEC procedures due to tumor recurrence. The detailed clinical and pathological characteristics were listed in [Table 1](#t0005){ref-type="table"}, and the major intraoperative parameters and surgical procedures were listed in [Table 2](#t0010){ref-type="table"}.

Survival of the Total Population {#s0055}
--------------------------------

By February 28, 2015, the median follow-up time was 45.8 months (range, 5.0-213.3), and 24 patients (52.1%) were deceased and 22 patients (47.8%) were still alive. The median OS was 57.5 months \[95% confidence interval (CI) 23.2-91.7\], and the 1-, 3-, 5-year survival rates were 97.8%, 65.2% and 56.5%, respectively ([Figure 1](#f0005){ref-type="fig"}).

Subgroup analysis was conducted. For group A of 16 patients with advanced EOC, the median PFS was not reached; for group B of 30 patients with recurrent EOC, the median PFS was 8.5 months (95% CI 0-17.5) (*P* = .034, log-rank test).

The median OS was 74.0 months (95% CI 8.5-139.5) in group A versus 57.5 months (95% CI 29.8-85.2) in group B (*P* = .68, log-rank test) ([Figure 2](#f0010){ref-type="fig"}*A*). The median OS for patients with LPCI (*n* = 24) versus HPCI (*n* = 22) was 76.6 months (95% CI 56.5-96.7) versus 38.5 months (95% CI 24.2-52.8) (*P* = .01, log-rank test) ([Figure 2](#f0010){ref-type="fig"}*B*). The median OS for patients with CC 0 to 1 versus CC 2 to 3 was 79.5 months (95% CI, 64.8-94.2) versus 24.3 months (95% CI 13.9-34.7) (*P* = .00, log-rank test) ([Figure 2](#f0010){ref-type="fig"}*C*). For recurrent patients, the median OS was 65.3 months (95% CI 42.6-88.9) for platinum-sensitive patients versus 20.0 months (95% CI 14.5-23.5) for platinum-resistant patients (*P* = .05, log-rank test) ([Figure 2](#f0010){ref-type="fig"}*D*).

Special Analysis on Patients with OS over 60 Months {#s0060}
---------------------------------------------------

By the last follow-up, there were 9 patients (19.6%) with OS over 60 months ([Table 3](#t0015){ref-type="table"}). Four patients had no evidence of tumor recurrence, with OS of 70.0, 72.5, 75.5, and 122.7 months, respectively. One patient was alive with tumor recurrence, living over 74.5 months by the time of this analysis. The other 4 patients died of tumor recurrence, with a median OS of 75.5 months (range, 65.3-204.0).

Detailed Description of Four Patients with Repeated CRS+HIPEC {#s0065}
-------------------------------------------------------------

There were four patients that each had two CRS+HIPEC treatments in this study including one primary advanced and three recurrent EOC patients. Two patients survived more than 5 years, and one patient was still alive without tumor with OS of 122.7 months. She reached CC 0 resection in two CRS+HIPEC procedure. The other 2 patients had OS of 38.4 and 38.5 months, respectively. The detailed information was listed in [Table 4](#t0020){ref-type="table"}.

SAE Analysis {#s0070}
------------

There was no 30-day perioperative death in this study. SAEs occurred in five patients, including small intestinal leakage in one patient, ascending colon leakage in one patient, protracted postoperative intestinal obstruction in one patient, wound infection with *Escherichia coli* sepsis in one patient, and pseudomembranous colitis in one patient. The detailed clinical course of these five patients was listed in [Table 5](#t0025){ref-type="table"}.

A binary logistic regression analysis was conducted to study the correlation of SAEs with major treatment parameters. There were no significant correlations between SAEs and age, FIGO stage, histopathology, organ and peritoneal resection area, PCI score, and CC score.

Tumor Recurrent after CRS+HIPEC {#s0075}
-------------------------------

At the time of last follow-up, tumor recurrence was documented in 35 cases, and most patients experienced tumor recurrence in more than 1 site ([Table 6](#t0030){ref-type="table"}). In terms of frequency, 26 (56.5%) patients had peritoneal recurrence including abdominopelvic mass, intestinal obstruction, and malignant ascites; 9 (19.6%) patients had lymphatic metastasis; 6 (13.0%) patients had hematogenous metastasis including liver, spleen, lung, and bone metastasis; and 6 (13.0%) patients had malignant pleural effusion.

Univariate and Multivariate Analysis on Predictors of OS {#s0080}
--------------------------------------------------------

A univariate analysis identified 3 covariates indicative of improved survival, including CC 0 to 1, PCI ≤ 20, and ascites ≤ 1000 ml. Multivariate Cox regression analysis identified CC scores as the only independent predictors for better survival. Compared with CC 2 to 3, CC 0 to 1 was about 7 times (hazard ratio = 7.2, 95% CI 1.9-27.0, *P* \< .01) more likely to improve survival ([Table 7](#t0035){ref-type="table"}).

Discussion {#s0085}
==========

In this study, we performed 50 CRS+HIPEC procedures as a comprehensive treatment strategy on 46 patients with advanced or recurrent EOC, achieving 1-, 3- and 5-year survival rates of 97.8%, 65.2%, and 56.5%, respectively. Of special note are the nine patients with OS \> 5 years, including four patients still disease free at the time of the most recent follow-up. Special analysis of these patients reveals several features. First, these patients were relatively young at the time of treatment. Among the 9 cases, there were 8 patients ≤ 65 years old and only 1 patient aged 67 years. Second, these patients had relatively low PCI at the time of surgery. Among the 9 cases, there were 8 patients with PCI \< 20 and only 1 patient with PCI 22. Third, these patients were mostly platinum-sensitive cases. Among the nine cases, eight patients were presumably platinum sensitive and 1 patient platinum resistant. Fourth, most patients had extensive CRS to achieve CC 0 to 1 (*n* = 8). Only one patient had CC 2 at the second CRS+HIPEC treatment.

As stage IIIc/IV and recurrent EOC are not curable by the current standard treatment of conventional surgery and taxane- and platinum-based SC [@bb0015], even with the recent addition of molecular targeting agents [@bb0080], [@bb0085], many surgical and gynecological oncologists have performed more extensive CRS to minimize tumor burden and HIPEC to eradicate microscopic residual tumors and free cancer cells after operation [@bb0090], [@bb0095], [@bb0100], [@bb0105], [@bb0110], [@bb0115]. This comprehensive treatment package integrates surgery, chemotherapy, and tumor heating and washing in one treatment setting, different from any other previously applied therapies that separate surgical therapy or medical therapy as independent treatments.

There have been several published studies on CRS+HIPEC to treat advanced EOC [@bb0120], [@bb0125], [@bb0130]. These studies achieved median OS of 28.5 to 77.8 months and 5-year survival rates of 28.0% to 72.0%. A multicenter phase II trial from Italy [@bb0120] to study upfront CRS+HIPEC for advanced EOC achieved a median PFS of 30.0 months and 5-year OS and PFS rates of 60.7% and 15.2%, respectively. Gonzalez et al. [@bb0130] studied the different time points of CRS+HIPEC to treat advanced EOC, and the median OS was 77.8 months for patients treated upfront, 62.8 months at first recurrence, and 35.7 months at second or subsequent recurrence. In our study, the 5-year survival rate for advanced EOC is similar to that reported in the literature.

Many studies also used CRS+HIPEC to treat recurrent EOC [@bb0115], [@bb0135], [@bb0140], achieving median OS of 37.0 to 48.9 months and 5-year survival rates of 35% to 41.3%. Our median OS was relatively higher than others, reaching 57.5 months (95% CI 29.8-85.2) in the recurrent group. Due to the heterogeneity of patient selection and complexity of this therapy strategy, most published reports were phase I [@bb0145] and phase II [@bb0150] studies, but the most recent phase III prospective randomized trial by Spiliotis et al. [@bb0090] on 120 patients with recurrent EOC has provided more convincing evidence. In this study, the mean OS was 26.7 versus 13.4 months for CRS+HIPEC group versus CRS alone group (*P* \< .01). Three-year survival rate was 75% for CRS+HIPEC group versus 18 % for CRS alone group (*P* \< .01).

One of the most important factors to determine the success of CRS+HIPEC is the PCI to reflect the degree of PC. In our study, the median PCI was 20, with 24 patients (52.2%) having PCI ≤ 20 and 22 patients (47.8%) having PCI \> 20. We found that patients with PCI ≤ 20 had median OS of 76.6 months, whereas those with PCI \> 20 had median OS of only 38.5 months (*P* = .01). At the same time, univariate analysis identified PCI ≤ 20 as an independent factor for better survival. So far, there has been no clear dividing line to determine the degree of PCI, although most reports used PCI 10 [@bb0115], 12 [@bb0155], and 15 [@bb0160], [@bb0165], [@bb0170] as the dividing line. All these studies indicated that patients with limited peritoneal cancer (relatively LPCI) could benefit more from this comprehensive treatment, emphasizing the importance of patient selection.

Complete CRS is another important factor for long-term survival. In our study, patients with CC 0 to 1 CRS had median OS of 79.5 months, whereas those with CC 2 to 3 had median OS of only 24.3 months. Multivariate Cox regression analysis also identified CC score as an independent factor for better survival. Compared with CC 2 to 3, CC 0 to 1 is about 7 times (hazard ratio = 7.2, 95% CI 1.9-27.0, *P* \< .01) more likely to improve survival. These findings are in accordance with the literature reports [@bb0100], [@bb0140]. Of special note is the exhaustive meta-analysis by Bristow et al. [@bb0175] on 81 clinical studies totaling 6995 EOC patients treated during the platinum era, which demonstrated that for every 10% increase in the rate of optimal CRS, there is a 3-month OS increase for patients with recurrent EOC. Therefore, every attempt should be tried to achieve maximal CRS. However, extensive surgery means high potential morbidity and mortality. In our experience, no perioperative death occurred, but five patients developed SAE, including two with intestinal fistula, two with severe infection and sepsis, and one patient with intestinal obstruction. Although binary logistic regression analysis revealed no significant correlations between SAEs and the clinical and operation variables, several factors deserve special attention: First, these five patients with SAE were all recurrent EOC; three were platinum sensitive and two were platinum resistant. Second, these patients had high PCI, 4 with PCI over 22 and only 1 with PCI 19. Third, these patients had high CC score, 3 with CC 2 to 3 and 2 with CC 1; there was no CC 0 patient. Fourth, SAE had significant detrimental impact on survival. Therefore, intensive perioperative risk factors management is warranted.

Conclusion {#s0090}
==========

In summary, this retrospective cohort study on a prospectively established database from China has provided evidence that CRS+HIPEC could bring OS benefits calculated from first treatment for advanced and recurrent EOC. More high-level evidence-based clinical studies are needed to validate this strategy.
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###### 

Major Clinicopathologic Characteristics of the 46 Patients[⁎](#tf0005){ref-type="table-fn"}

  Items                                                                                       Value, n (%)
  ------------------------------------------------------------------------------------------- --------------
  Median age (years)                                                                          58
   \< 60                                                                                      25 (54.3)
   ≥ 60                                                                                       21 (45.7)
  Median Karnofsky performance score (range)                                                  70 (50-90)
  HIPEC timing                                                                                
   Primary (IIIc/IV)                                                                          16 (34.8)
   Recurrent                                                                                  30 (65.2)
  Histopathology                                                                              
   Serous adenocarcinoma                                                                      34 (73.9)
   Mucinous adenocarcinoma                                                                    11 (23.9)
   Endometrioid carcinoma                                                                     1 (2.2)
  Histopathology differentiation                                                              
   Well differentiated                                                                        11 (23.9)
   Intermediately/poorly differentiated                                                       35 (76.1)
  Comorbidity                                                                                 
   Yes                                                                                        18 (39.1)
   No                                                                                         28 (60.9)
  Neoadjuvant chemotherapy for primary EOC PC                                                 
   Yes                                                                                        5 (31.2)
   No                                                                                         11 (68.8)
  SAE[⁎](#tf0005){ref-type="table-fn"}                                                        
   Yes                                                                                        5 (10.0)
   No                                                                                         45 (90.0)
  Median postoperative chemotherapy cycles[†](#tf0010){ref-type="table-fn"}                   6
   \< 6                                                                                       17 (37.0)
   ≥ 6                                                                                        29 (63.0)
  Median postoperative intraperitoneal chemotherapy cycles[†](#tf0010){ref-type="table-fn"}   3
  Median postoperative hospital stay (days) (range)[⁎](#tf0005){ref-type="table-fn"}          11 (4-43)
  Median ICU stay (hours) (range)[⁎](#tf0005){ref-type="table-fn"}                            15 (0-89)
  Median gastric tube removal time (days) (range)[⁎](#tf0005){ref-type="table-fn"}            5 (2-13)
  Platinum sensitivity for recurrent patients (*n* = 30)                                      
   Sensitive                                                                                  16 (53.3)
   Nonsensitive                                                                               14 (46.7)

A total of 50 CRS+HIPEC procedures were performed for 46 patients, including 4 patients each having 2 procedures.

According to the first CRS+HIPEC procedure.

###### 

Intraoperative Parameters of the 46 EOC PC Patients

  Items                                                     Value, n (%)
  --------------------------------------------------------- ------------------
  PCI                                                       
   Median PCI (range)                                       20 (7-39)
   ≤ 20                                                     24 (52.2)
   \> 20                                                    22 (47.8)
  CC scores                                                 
   0-1                                                      28 (60.9)
   2-3                                                      18 (39.1)
  Surgical procedures; organ resection                      
   Resection of jejunum                                     1 (0.2)
   Resection of ileum                                       7 (15.0)
   Right colectomy                                          17 (26.1)
   Transverse colectomy                                     4 (8.7)
   Descending colectomy                                     3 (6.5)
   Sigmoidectomy                                            6 (13.0)
   Rectectomy                                               9 (19.6)
   Splenectomy                                              4 (8.7)
   Resection of ovarian/fallopian tube                      16 (34.8)
   Hysterectomy                                             7 (15.0)
   Partial hepatectomy                                      1 (0.2)
   Cholecystectomy                                          4 (8.7)
   Appendectomy                                             7 (15.0)
   Partial gastrectomy                                      1 (0.2)
  Number of organ resected                                  
   0 resection                                              15 (32.6)
   1-3 resections                                           24 (52.2)
   4-8 resections                                           7 (15.0)
  Peritonectomy                                             
   Greater/lesser/omentum                                   46 (100.0)
   Left diaphragmatic copula                                5 (10.9)
   Right diaphragmatic copula                               23 (50.0)
   Right colon gutter                                       22 (47.8)
   Left colon gutter                                        17 (37.0)
   Liver round ligament/sickle ligament                     46 (100.0)
   Douglas pouch                                            23 (50.0)
   Anterior wall peritoneum                                 12 (26.1)
   Pelvic peritoneum                                        34 (73.9)
   Mesenteric fulguration                                   33 (71.7)
  Peritoneal regions resected                               
   1-3 regions                                              17 (37.0)
   4-6 regions                                              15 (32.6)
   7-10 regions                                             14 (30.4)
  Number of anastomosis                                     
   None or stoma only                                       30 (65.2)
   = 1                                                      12 (26.1)
   \> 1                                                     4 (8.7)
  Fluid output volume at surgery (median, range) (ml)       
   Blood loss                                               600 (100-2000)
   Urine output                                             1000 (100-3350)
  Ascites                                                   1000 (0-4500)
   ≤ 1000                                                   25 (54.3)
   \> 1000                                                  21 (45.7)
  Fluid intake volume at surgery (median, range)            
   Plasma (ml)                                              450 (0-1550)
   Red blood cells (U)[⁎](#tf0015){ref-type="table-fn"}     3 (0-16)
   Cryoprecipitation (U)[†](#tf0030){ref-type="table-fn"}   4 (0-14)
   Other fluids (ml)                                        4000 (2000-8000)
  CRS+HIPEC duration (median, range) (h)                    7.5 (4.5-13.5)

1 U = 200 ml.

1 U = 25 ml.

###### 

Major Clinicopathological Features of 9 Patients with OS \> 60 Months

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.   Age (Years)   P/R   Histopathology                                                      CRS[⁎](#tf0020){ref-type="table-fn"}                                                                                                                                                    HIPEC                                                                               PCI               CC        OS/PFS (Months)   Comments
  ----- ------------- ----- ------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------- ----------------- --------- ----------------- --------------------------------------------------------------------------------------------------------------------------
  1     43            P     Serous-mucinous cystadenocarcinoma, moderately differentiated       Resection of pelvic peritoneum, anterior wall peritoneum, hysterectomy and resection of bilateral ovarian/fallopian tube, mesenteric fulguration                                        DDP 100 mg/m^2^, MMC 20 mg/m^2^                                                     15                0         70.0/70.0, DFS    Comorbidity: poliomyelitis sequel period, polycystic liver, and polycystic kidney

  2     62            P     Serous papillary adenocarcinoma, moderately differentiated          Right diaphragmatic copula peritoneum, left/right paracolic sulci peritoneum, pelvic peritoneum, liver round ligament resection, hysterectomy and resection of ovarian/fallopian tube   DDP 100 mg/m^2^, MMC 20 mg/m^2^                                                     19                1         74.5/16.5, SWT    Pleurectomy and hyperthermic intrathoracic chemotherapy were conducted 2 years after CRS+HIPEC due to pleural metastasis

  3     32            P     Mucinous cystadenocarcinoma, well differentiated                    Resection of bilateral ovarian/fallopian tube, pelvic peritoneum, and liver round ligament                                                                                              DDP 100 mg/m^2^, MMC 20 mg/m^2^                                                     15                0         72.5/72.5, DFS    

  4     49            R     Serous papillary adenocarcinoma, moderately-poorly differentiated   Sigmoidectomy, rectectomy, resection of pelvic peritoneum                                                                                                                               DDP 100 mg/m^2^, MMC 20 mg/m^2^                                                     11                1         75.5/72.5, DFS    

  5     57            R     Borderline serous cystadenocarcinoma, moderately differentiated     Resection of right paracolic sulci peritoneum, pelvic peritoneum, anterior wall peritoneum                                                                                              DDP 100 mg/m^2^, MMC 20 mg/m^2^                                                     16                0         76.6/18.0, D      

  6     50            R     Serous papillary adenocarcinoma, moderately-poorly differentiated   1st: ileectomy, resection of anterior wall peritoneum\                                                                                                                                  1st: DDP 100 mg/m^2^, MMC 20 mg/m^2^, 2nd: Lobaplatin 50 mg/m^2^, TAX 100 mg/m^2^   1st: 20 2nd: 22   1st: 1\   65.3/8.5, D       Intraperitoneal extensive bowel adhesions were found at the second operation
                                                                                                2nd: resection of pelvic peritoneum, anterior wall peritoneum and bilateral fossa iliaca peritoneum, mesenteric fulguration                                                                                                                                                                   2nd: 2                      

  7     67            R     Endometrioid carcinoma, poorly differentiated                       Resection of right paracolic sulci peritoneum, right diaphragmatic copula peritoneum, pelvic peritoneum, anterior wall peritoneum                                                       DDP 100 mg/m^2^, MMC 20 mg/m^2^                                                     16                1         204.0/54.0,D      A total of 4 operations and 2 TACEs were implemented from first treatment to death

  8     51            R     Borderline mucinous cystadenocarcinoma, moderately differentiated   Resection of left/right diaphragmatic copula peritoneum, left/right paracolic sulci, pelvic peritoneum and bilateral fossa iliaca peritoneum                                            DDP 100 mg/m^2^, MMC 20 mg/m^2^                                                     22                1         79.5/16.0, D      SAE: small intestinal leakage, abdominal infection (*Proteus mirabilis* infection)

  9     60            R     Mucinous cystadenocarcinoma, moderately differentiated              1st: greater/lesser omentectomy, appendicectomy\                                                                                                                                        1st: DDP 100 mg/m^2^, MMC 20 mg/m^2^, 2nd: Lobaplatin 50 mg/m^2^, TAX 100 mg/m^2^   1st: 5 2nd: 8     1st: 0\   122.7/58.0,DFS    Comorbidity: hypertension; type 2 diabetes mellitus
                                                                                                2nd: resection of ileocecum, left/right diaphragmatic copula peritoneum and ascending colon                                                                                                                                                                                                   2nd: 0                      
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*P*, primary; *R*, recurrent; *DDP*, *cis*-platinum; *TAX*, paclitaxel; *TACE*, transcatheter arterial chemoembolization; *DFS*, disease-free survival; *SWT*, survival with tumor; *D*, died.

PFS was calculated from the first CRS+HIPEC in this table.

Greater omentectomy and lesser omentectomy were performed on all the nine patients.

###### 

Major Clinicopathological Features on 4 Patients Undergoing Twice CRS+HIPEC Procedures

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.   Age (Years)   P/R   Histopathology                                                      CRS                                                                                                                                                                                                                                                                                         HIPEC                                          PCI                CC               OS/PFS (Months)                            Comments
  ----- ------------- ----- ------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------- ------------------ ---------------- ------------------------------------------ ---------------------------------------------------------------------------------------------------------------
  1     50            R     Serous papillary adenocarcinoma, moderately-poorly differentiated   1st: ileectomy, resection of anterior wall peritoneum;\                                                                                                                                                                                                                                     1st: DDP 100 mg/m^2^, MMC 20 mg/m^2^,\         1st: 20, 2nd: 22   1st: 1, 2nd: 2   OS: 65.3, PFS 1: 8.5, PFS 2: 6.0, D        Intraperitoneal extensive bowel adhesions were found at the second operation
                                                                                                2nd: resection of pelvic peritoneum, anterior wall peritoneum and bilateral fossa iliaca peritoneum, mesenteric fulguration                                                                                                                                                                 2nd: lobaplatin 50 mg/m^2^, TAX 100 mg/m^2^                                                                                   

  2     60            R     Mucinous cystadenocarcinoma, moderately differentiated              1st: greater/lesser omentectomy, appendicectomy\                                                                                                                                                                                                                                            1st: DDP 100 mg/m^2^, MMC 20 mg/m^2^,\         1st: 5, 2nd: 8     1st: 0, 2nd: 0   OS: 122.7, PFS 1: 58.0, PFS 2: 19.6, DFS   Comorbidity: hypertension; type 2 diabetes mellitus
                                                                                                2nd: resection of ileocecum, left/right diaphragmatic copula peritoneum and ascending colon                                                                                                                                                                                                 2nd: lobaplatin 50 mg/m^2^, TAX 100 mg/m^2^                                                                                   

  3     61            P     Serous papillary adenocarcinoma, moderately-poorly differentiated   1st: right hemicolectomy, splenectomy, cholecystectomy, hysterectomy and resection of bilateral ovarian/fallopian tube. Greater/lesser omentectomy, resection of right diaphragmatic copula peritoneum, right/left paracolic sulci peritoneum, pelvic peritoneum, mesenteric fulguration\   1st: lobaplatin 50 mg/m^2^, TAX 100 mg/m^2^\   1st: 22, 2nd: 23   1st: 1, 2nd: 2   OS: 38.4, PFS 1: 14.0, PFS 2: 5.1, SWT     
                                                                                                2nd: partial gastrectomy, resection of anterior wall peritoneum, bilateral fossa iliaca peritoneum, mesenteric fulguration                                                                                                                                                                  2nd: lobaplatin 50 mg/m^2^, TAX 100 mg/m^2^                                                                                   

  4     69            R     Serous adenocarcinoma, poorly differentiated                        1st: transverse colectomy, resection of right/left diaphragmatic copula peritoneum, right/left paracolic sulci peritoneum, pelvic peritoneum, mesenteric fulguration\                                                                                                                       1st: DDP 100 mg/m^2^, MMC 20 mg/m^2^,\         1st: 15, 2nd: 23   1st: 1, 2nd: 2   OS: 38.5, PFS 1:10.0, PFS 2:8.0, D         Grade 4 myelosuppression during postoperative chemotherapy; comorbidity: hypertension; coronary heart disease
                                                                                                2nd: proctosigmoidectomy, resection of bilateral fossa iliaca peritoneum, mesenteric fulguration                                                                                                                                                                                            2nd: lobaplatin 50 mg/m^2^, TAX 100 mg/m^2^                                                                                   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*PFS 1*, from the first CRS+HIPEC to disease progression; *PFS 2*, from the second CRS+HIPEC to disease progression.

###### 

Detailed Data on 5 Patients with SAE[⁎](#tf0025){ref-type="table-fn"}

  No.   Age (Years)   P/R   Histopathology                                                      CRS                                                                                                                                                                                            HIPEC                                                   PCI   CC   SAE                                                                                             Treatment   OS (Months)
  ----- ------------- ----- ------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------- ----- ---- ----------------------------------------------------------------------------------------------- ----------- -------------
  1     67            R     Serous papillary adenocarcinoma, moderately differentiated          Greater omentectomy, mesenteric fulguration                                                                                                                                                    DDP 100 mg/m^2^, MMC 20 mg/m^2^                         39    3    Ascending colon leakage (POD 8), abdominal MRSA infection (POD 12)                              CT          32.3, D
  2     51            R     Borderline mucinous cystadenocarcinoma, moderately differentiated   Resection of left/right diaphragmatic copula peritoneum, left/right paracolic sulci, pelvic peritoneum and bilateral fossa iliaca peritoneum                                                   DDP 100 mg/m^2^, MMC 20 mg/m^2^                         22    1    Small intestinal leakage (POD 6), abdominal infection (*Proteus mirabilis* infection, POD 15)   CT          79.5, D
  3     56            R     Serous cystadenocarcinoma, poorly differentiated                    Left hemicolectomy, left lower quadrant abdominal giant tumor resection, resection of part left upper quadrant of the abdomen peritoneum and round ligament of liver, mesenteric fulguration   Lobaplatin 50 mg/m^2^, TAX 100 mg/m^2^                  19    1    Tumor recurrence, abdominal giant lump, intestinal obstruction (POD 14)                         CT          32.9, D
  4     55            R     Serous papillary adenocarcinoma, moderately differentiated          Greater omentectomy, ileectomy, sigmoid colon and rectum resection, peritonectomy of the pelvis, right and left paracolic gutter, round ligament of liver resection                            Lobaplatin 50 mg/m^2^, TAX 100 mg/m^2^                  33    3    Infection of incisional wound with *Escherichia coli* sepsis (POD 14)                           CT          16.3, D
  5     44            R     Serous papillary cystadenocarcinoma, poorly differentiated          Greater/lesser omentectomy, splenectomy, cholecystectomy, right hemicolectomy, sigmoidectomy, rectectomy, right diaphragmatic copula, anterior wall and pelvic peritonectomy                   Lobaplatin 50 mg/m^2^, TAX 100 mg/m^2^, 43 °C, 60 min   33    2    Pseudomembranous colitis (POD 14)                                                               CT          6.2, D

*POD*, postoperative days; *CT*, conservative treatment; *MRSA*, methicillin-resistant *Staphylococcus aureus*.

Common Terminology Criteria for Adverse Events version 4.0.

###### 

The Sites of Recurrence following HIPEC for the 46 Patients

  Item                                                                                               N (%)
  -------------------------------------------------------------------------------------------------- ------------
  Peritoneal recurrence (including abdominopelvic mass, intestinal obstruction, malignant ascites)   26 (56.5%)
  Hematogenous (including liver, spleen, lung, bone metastasis)                                      6 (13.0)
  Lymphatic metastasis                                                                               9 (19.6)
  Malignant pleural effusion                                                                         6 (13.0)
  Malignant ascites only                                                                             10 (21.7)
  The second primary tumor                                                                           1 (2.1)
  Intestinal obstruction                                                                             6 (13.0)

###### 

Univariate and Multivariate Analysis of Independent Factors Influencing OS

  Covariate                                  Univariate Analysis   Multivariate Analysis                                                     
  ------------------------------------------ --------------------- ----------------------- ------- -------------- ------- ---------- ------- --------------
  CC score (CC 0-1 vs CC 2-3)                17.399                **.000**                7.937   3.003-12.277   8.743   **.003**   7.246   1.949-27.027
  PCI (≤ 20 vs \> 20)                        5.998                 **.014**                2.941   1.241-6.993    0.005   .943       1.045   0.316-3.455
  Ascites (≤ 1000 ml vs \> 1000 ml)          3.841                 **.050**                2.398   1.000-5.747    1.341   .247       1.686   0.696-4.082
  Age (≥ 60 vs \< 60)                        0.726                 .394                    1.436   0.625-3.301                               
  Differentiated (well vs moderate/poorly)   1.517                 .218                    2.000   0.664-6.024                               
  Comorbidity (yes vs no)                    1.203                 .273                    1.616   0.685-3.809                               
  HIPEC timing (primary vs recurrent)        0.170                 .680                    1.220   0.475-3.135                               
  NACT (yes vs no)                           0.535                 .465                    1.456   0.532-3.984                               
  PIC (yes vs no)                            0.422                 .516                    1.315   0.575-3.006                               
  SAE (yes vs no)                            1.114                 .291                    1.610   0.664-3.906                               

*NACT*, neoadjuvant chemotherapy.

[^1]: Contributed equally to this work.
